FDA Approves Cosibelimab for Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

FDA

The FDA has approved cosibelimab-ipdl (Unloxcyt) for the treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) who are not candidates for curative surgery or radiation.

The regulatory decision was based on data from the phase 1 Study CK-301-101 (NCT03212404) in which the agent elicited an objective response rate (ORR) of 47% (95% CI, 36%-59%) by independent central review (ICR) assessment in those with metastatic disease (n = 78) and 48% (95% CI, 30%-67%) in those with locally advanced disease (n = 31). The median duration of response (DOR) was not reached (range, 1.4+ to 34.1+) and 17.7 months (range, 3.7+ to 17.7) in the respective groups.

"Today’s FDA approval of Unloxcyt – the first marketing approval for our company – is a significant milestone both for Checkpoint and for patients with advanced CSCC,” James Oliviero, president and chief executive officer of Checkpoint Therapeutics, stated in a news release.² “This approval marks Checkpoint’s transformation to a commercial-stage company, with the opportunity to compete in a US market estimated to exceed $1 billion annually, where we believe Unloxcyt offers a differentiated treatment option vs available therapies by binding to PD-L1, rather than programmed death receptor-1, to release the inhibitory effects of PD-L1 on the antitumor immune response. Additionally, Unloxcyt has demonstrated the ability to induce antibody-dependent cell-mediated cytotoxicity, another potential differentiating feature of the drug compared to existing marketed therapies for patients with CSCC.”

About Study CK-301-101

The multicenter, multicohort, open-label trial enrolled a total of 109 patients with metastatic or locally advanced CSCC who were not eligible to undergo surgery or radiation with curative intent.^1,3 If patients had active or suspected autoimmune disease, underwent allogeneic transplant within 6 months before treatment, had prior exposure to an anti-PD-(L)1 therapy or other immune checkpoint inhibition, had uncontrolled or significant cardiovascular disease, an ECOG performance status greater than 2, or human immunodeficiency virus, hepatitis B virus, or hepatitis C virus, they were excluded.

Participants were administered cosibelimab at 800 mg every 2 weeks until progressive disease or intolerable toxicity.

The study's major efficacy outcome measures were ORR and DOR per IRC assessment and RECIST v 1.1 criteria. For those with locally advanced disease who had externally visible target lesions that were not evaluable via radiologic imaging, ORR was determined by ICR assessments of digital photography.

About the Patient Population

The median age was 75 years (range, 37-95) with most patients at least 65 years (78%). Moreover, more than half of patients were male (72%) and White (85%). Regarding ECOG performance status, 34% of patients had a status of 0 and 66% had a status of 1. Seven percent of patients previously received at least 1 anticancer systemic therapy. Moreover, 66% and 69% of patients had prior surgery or radiotherapy, respectively.

Additional Efficacy Insights

In the subset of patients with metastatic disease who responded to cosibelimab, 8% had a complete response (CR) and 40% had a partial response (PR). Of the 37 responders, 84% experienced a DOR that lasted for at least 6 months and 54% experienced a DOR that lasted for at least 1 year. In the subset of patients with locally advanced disease who responded to the agent, the CR and PR rates were 10% and 39%, respectively. Of the 15 responders, 87% experienced a DOR that lasted for 6 months or longer and 20% had a DOR that lasted for 12 months or longer.

Safety Insights

The safety of cosibelimab was examined in a total of 141 patients with metastatic or locally advanced CSCC enrolled in Study CK-301-101. Patients received the agent at 800 mg every 2 weeks (n = 115) or 1200 mg every 3 weeks (n = 26). The median duration of exposure to the agent was 36 weeks (range, 2 weeks to 3.7 years).

Serious adverse effects (AEs) occurred in 31% of patients with advanced disease. Dose interruption due to AEs was required in 36% of patients and 8% of patients experienced AEs that led to permanent treatment discontinuation.

The most common AEs experienced by at least 10% of patients included fatigue (all grade, 33%; grade 3/4, 3%), musculoskeletal pain (25%; 3%), rash (23%; 1%), hypothyroidism (14%; 0%), diarrhea (14%; 0%), nausea (13%; 0%), constipation (13%; 0%), headache (12%; 0%), pruritus (12%; 0%), edema (11%; 0%), localized infection (10%; 0.7%), and urinary tract infection (10%; 0%).

Laboratory abnormalities that worsened from baseline to grade 3 or 4 and occurred in at least 1% of patients included decreased hemoglobin (all grade, 45%; grade 3/4, 4%), decreased lymphocytes (41%; 6%), decreased sodium (38%; 5%), increased alkaline phosphatase (26%; 1%), increased alanine transferase (25%; 4%), increased lipase (25%; 3%), increased aspartate aminotransferase (24%; 3%), increased potassium (23%; 3%), increased calcium (14%; 2%), decreased platelets (14%; 1%), and decreased leukocytes (10%; 1%).

References

1. FDA approves cosibelimab-ipdl for metastatic or locally advanced cutaneous squamous cell carcinoma. FDA. December 13, 2024. Accessed December 13, 2024. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-cosibelimab-ipdl-metastatic-or-locally-advanced-cutaneous-squamous-cell-carcinoma
2. Checkpoint Therapeutics announces FDA approval of UNLOXCYT™ (cosibelimab-ipdl). Checkpoint Therapeutics. December 13, 2024. Accessed December 13, 2024. https://ir.checkpointtx.com/news-events/press-releases/detail/127/checkpoint-therapeutics-announces-fda-approval-of
3. Cosibelimab-ipdl. Prescribing information. Checkpoint Therapeutics; 2024. Accessed December 13, 2024. https://checkpointtx.com/wp-content/uploads/2024/12/uspi-unloxcyt.pdf